Fairvalue-Calculator Fairvalue-Calculator
EN DE

Evofem Biosciences, Inc (EVFM) Fair Value & Analysis

Healthcare · US · Market cap $1.2M

Price$0.0090
Fair Value$0.0090
Upside-0.5%
Quality95/100
Evidence: Medium Range $0.0085 – $0.0092

Fair value as of: Jun 26, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Evofem Biosciences, Inc (EVFM) currently trades at $0.0090, while our model-based Fair Value estimate is $0.0090 — implying the stock looks roughly 0.5% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).

About the company

Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. The company's commercial products include PHEXXI, a hormone-free contraceptive vaginal gel; and SOLOSEC, a single-dose oral antimicrobial agent for the treatment of bacterial vaginosis and trichomoniasis. Evofem Biosciences, Inc. is headquartered in San Diego, California.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -88% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -27% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -62%

Frequently asked questions

Is Evofem Biosciences, Inc (EVFM) undervalued?
As of Jun 26, 2026, our model estimates a fair value of $0.0090 versus a price of $0.0090 — about −1% (overvalued). Model-based estimate, not financial advice.
What is the fair value of EVFM?
Our 21-model fair value for Evofem Biosciences, Inc is $0.0090 (as of Jun 26, 2026), built from audited fundamentals. The current price is $0.0090.
What is the quality score of EVFM?
Evofem Biosciences, Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.